iifl-logo-icon 1

Ind-Swift Laboratories Ltd Share Price

134.52
(-0.04%)
Jul 12, 2024|03:32:24 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open134.73
  • Day's High135.9
  • 52 Wk High139
  • Prev. Close134.58
  • Day's Low133
  • 52 Wk Low81.85
  • Turnover (lac)314.65
  • P/E5.45
  • Face Value10
  • Book Value153.94
  • EPS24.63
  • Mkt. Cap (Cr.)794.84
  • Div. Yield0
No Records Found

Ind-Swift Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

134.73

Prev. Close

134.58

Turnover(Lac.)

314.65

Day's High

135.9

Day's Low

133

52 Week's High

139

52 Week's Low

81.85

Book Value

153.94

Face Value

10

Mkt Cap (₹ Cr.)

794.84

P/E

5.45

EPS

24.63

Divi. Yield

0

Ind-Swift Laboratories Ltd Corporate Action

31 Aug 2023

12:00 AM

AGM

Announcement Date: 31 Aug, 2023

arrow

12 Sep 2023

12:00 AM

BookCloser

arrow

24 Jun 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

6 Sep 2023

12:00 AM

EGM

arrow

Ind-Swift Laboratories Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ind-Swift Laboratories Ltd SHAREHOLDING SNAPSHOT

13 Jul, 2024|07:10 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 42.00%

Foreign: 0.00%

Indian: 42.00%

Non-Promoter- 8.27%

Institutions: 8.27%

Non-Institutions: 49.71%

Custodian: 0.00%

Share Price

Ind-Swift Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

59.81

59.81

59.81

59.81

Preference Capital

0

0

0

0

Reserves

615.54

572.75

578.89

584.8

Net Worth

675.35

632.56

638.7

644.61

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

856.57

751.83

731.29

693.71

yoy growth (%)

13.93

2.8

5.41

8.6

Raw materials

-424.99

-378.84

-375.06

-395.81

As % of sales

49.61

50.38

51.28

57.05

Employee costs

-104.16

-100.37

-89.3

-71.61

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

16.11

-19.56

30.51

-50.85

Depreciation

-87.29

-90.05

-86.61

-88.25

Tax paid

-20.51

-1.22

-10.95

16.46

Working capital

24.4

224.01

-12.39

-206.93

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

13.93

2.8

5.41

8.6

Op profit growth

27.14

11.71

20.97

-3.11

EBIT growth

32.31

49.44

56.9

-0.94

Net profit growth

-78.84

-217.94

-144.36

-32.51

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,280.9

1,207.31

1,038.73

891.34

779.64

Excise Duty

0

0

0

0

0

Net Sales

1,280.9

1,207.31

1,038.73

891.34

779.64

Other Operating Income

0

0

0

0

0

Other Income

431.96

33.5

43.5

22.7

33.4

Ind-Swift Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,581.75

124.473,79,874.71867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,582.5

77.171,21,620.455310.652,259507.93

Cipla Ltd

CIPLA

1,506

32.731,21,596.061,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,163.35

33.971,17,155.821,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,594.75

25.681,10,037.531,034.80.615,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ind-Swift Laboratories Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

N R Munjal

Joint Managing Director

Himanshu Jain

Company Sec. & Compli. Officer

Pradeep Verma

Executive Director

Rishav Mehta

Independent Director

S P Sharma

Independent Director

Neerja Chathley

Independent Director

Ashwani K Vig

Executive Director

Sahil Munjal

Independent Director

Rajendra Kumar Gupta

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA.Ind-Swift Laboratories Ltd was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they enter
Read More

Company FAQs

What is the Ind-Swift Laboratories Ltd share price today?

Down Arrow

The Ind-Swift Laboratories Ltd shares price on N/A is Rs.₹134.5 today.

What is the Market Cap of Ind-Swift Laboratories Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ind-Swift Laboratories Ltd is ₹794.72 Cr. as of 12 Jul ‘24

What is the PE and PB ratio of Ind-Swift Laboratories Ltd?

Down Arrow

The PE and PB ratios of Ind-Swift Laboratories Ltd is 5.45 and 1.07 as of 12 Jul ‘24

What is the 52 Week High and Low of Ind-Swift Laboratories Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Ind-Swift Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ind-Swift Laboratories Ltd is ₹82 and ₹139.35 as of 12 Jul ‘24

What is the CAGR of Ind-Swift Laboratories Ltd?

Down Arrow

Ind-Swift Laboratories Ltd's CAGR for 5 Years at 33.02%, 3 Years at 6.45%, 1 Year at 61.28%, 6 Month at 23.21%, 3 Month at 3.54% and 1 Month at 13.19%.

What is the shareholding pattern of Ind-Swift Laboratories Ltd?

Down Arrow

The shareholding pattern of Ind-Swift Laboratories Ltd is as follows:
Promoters - 42.00 %
Institutions - 8.28 %
Public - 49.72 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.